In patients with moderate aortic stenosis (AS) and heart failure with reduced ejection fraction (HFrEF) on guideline-directed medical therapy, transcatheter aortic valve replacement (TAVR) was not superior to general AS surveillance for the composite endpoint of the TAVR UNLOAD trial.